孕产妇B族链球菌免疫:免疫相关物、微生物组权衡与全球实施挑战
综述整合免疫保护相关物、抗生素预防的微生物组权衡及全球实施挑战三个维度,批判性审视孕产妇GBS疫苗研发进展。文章强调现有产时抗生素预防不能预防晚发型疾病、母体定植或死产,在低收入国家实施困难,疫苗为有前景的补充策略。
要点
- 产时抗生素预防不能预防晚发型GBS疾病、母体定植或GBS相关死产。
- 疫苗监管决策需明确血清学和功能性免疫保护相关物,仍存不确定性。
- 围产期抗生素暴露与微生物组扰动相关,但临床意义尚不明确。
核心结论
- 孕产妇GBS疫苗是补充现有抗生素预防、实现更广泛公平预防的有前景策略。
- 疫苗评估与监管路径需整合免疫学、生物学和实施框架。
研究设计与样本
- 综述,整合免疫保护相关物、微生物组权衡和全球实施挑战三个维度。
主要发现
- 产时抗生素预防在高收入国家显著减少早发型GBS疾病,但不预防晚发型疾病、母体定植或GBS相关死产。
- 产时抗生素预防在低收入和中等收入国家实施具有挑战性。
- 围产期抗生素暴露与微生物组扰动相关,但其临床意义当前不确定。
- 定义监管决策所需的血清学和功能性免疫保护相关物仍存在不确定性。
临床怎么用
- 疫苗上市临近时,需以免疫学、生物学和实施框架指导疫苗评估、监管路径和政策决策。
局限性
- 微生物组扰动的临床意义当前不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Group B Streptococcus (GBS) remains a leading cause of neonatal sepsis, meningitis, stillbirth, and long-term neurodevelopmental impairment worldwide. Although intrapartum antibiotic prophylaxis (IAP) has substantially reduced early-onset GBS disease in high-income settings and remains an effective and evidence-based intervention, it does not prevent late-onset disease, maternal colonization, or GBS-associated stillbirths, and its implementation is challenging in many low- and middle-income countries (LMICs). Maternal vaccination has therefore emerged as a promising complementary strategy to achieve broader, more equitable prevention of GBS disease. This review critically examines current progress in maternal GBS vaccine development by integrating three interrelated dimensions that will shape future vaccine impact: immune correlates of protection, microbiome-related trade-offs of existing antibiotic-based prevention strategies, and global implementation challenges. We highlight recent advances and remaining uncertainties in defining serological and functional immune correlates required for regulatory decision-making, discuss emerging evidence on microbiome perturbations associated with peripartum antibiotic exposure while emphasizing their currently uncertain clinical significance, and analyze operational and policy considerations relevant to vaccine introduction in LMICs. By moving beyond descriptive summaries of the vaccine development pipeline, this review provides an integrated immunological, biological, and implementation-focused framework to inform vaccine evaluation, regulatory pathways, and policy decisions as maternal GBS vaccines approach licensure and global deployment.
引用
- Ikrar T, Muchsin W, Sophian A, et al. Maternal immunization against group B Streptococcus: Immune correlates, microbiome trade-offs, and global implementation challenges. Vaccine. 2026. PMID: 41719865. doi:10.1016/j.vaccine.2026.128381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。